Steven Cox, DO
Family Medicine · Norman, OKNPI 1306958889
Payments from drug & device makers
Across 2,399 payments — averaging $2886.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2.7M
- Emergent Biosolutions Inc.$1.2M
- Alnylam Pharmaceuticals Inc.$596K
- GSK$536K
- Boehringer Ingelheim$517K
- Modernatx, Inc.$342K
- plus $1M from 24 others
Across 4 payments — averaging $10,508 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$42K
What the payments were for
- Consulting fees$1,40014%
- Travel & lodging$2,50425%
- Food & beverage$6,02260%
- Education$250%
- Gifts$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 196 | $2,733,509 |
| Emergent Biosolutions Inc. | 711 | $1,190,689 |
| Alnylam Pharmaceuticals Inc. | 478 | $596,418 |
| GSK | 59 | $536,250 |
| Boehringer Ingelheim | 15 | $517,324 |
| Modernatx, Inc. | 529 | $341,867 |
| Merck | 59 | $319,665 |
| AbbVie(2 entities) | 59 | $196,758 |
| Johnson & Johnson | 51 | $180,832 |
| Bavarian Nordic A/s | 20 | $139,793 |
| Sanofi Pasteur Inc. | 8 | $61,646 |
| Eli Lilly | 3 | $52,650 |
| AstraZeneca | 33 | $28,207 |
| Boehringer Ingelheim International GmbH | 109 | $23,787 |
| Amgen | 12 | $3,250 |
| Novo Nordisk | 14 | $551 |
| Amarin Pharma, Inc. | 15 | $428 |
| Regeneron Healthcare Solutions, Inc. | 2 | $191 |
| Lilly USA, LLC | 9 | $161 |
| Antares Pharma, Inc. | 3 | $160 |
| Novartis | 2 | $145 |
| Regeneron | 1 | $125 |
| Biohaven Pharmaceuticals, Inc. | 1 | $102 |
| Teva Pharmaceuticals USA, Inc. | 1 | $87 |
| Exact Sciences | 3 | $52 |
| Vanda Pharmaceuticals Inc. | 1 | $30 |
| Eisai Inc. | 2 | $29 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Mannkind Corporation | 1 | $20 |
| Vivus LLC | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,924,771 in reported general payments places this provider in the 95th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 60 | $57,313 |
| MounjaroTirzepatide | 46 | $49,418 |
| OzempicSemaglutide | 39 | $36,475 |
| TrulicityDulaglutide | 26 | $24,480 |
| JanuviaSitagliptin Phosphate | 18 | $18,696 |
| JardianceEmpagliflozin | 25 | $17,817 |
| EliquisApixaban | 23 | $14,128 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $12,972 |
| VascepaIcosapent Ethyl | 17 | $8,646 |
| XareltoRivaroxaban | 11 | $6,842 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 183 | $6,393 |
| Atorvastatin Calcium | 117 | $3,653 |
| Rosuvastatin Calcium | 178 | $3,366 |
| Nebivolol Hcl | 52 | $3,236 |
| Gabapentin | 107 | $3,077 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $161 | $73,89872 claims |
| AstraZenecaFarxiga | $28,207 | $57,31360 claims |
| Novo NordiskOzempic | $551 | $36,47539 claims |
| MerckJanuvia | $319,665 | $18,69618 claims |
| Boehringer IngelheimJardiance | $517,324 | $17,81725 claims |
| PfizerEliquis, Paxlovid | $2,733,509 | $15,55737 claims |
| GSKTrelegy Ellipta | $536,250 | $12,97219 claims |
| Johnson & JohnsonXarelto | $180,832 | $6,84211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Norman
- Lisa ConneryNorman$15.6M
- Rachel AndersonNorman$2.8M
- Carl GriffinOklahoma City$28.2M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Alexander FrankOklahoma City$3.1M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
- Richard LowranceMustang$758K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.